

INFORMATION DISCLOSURE STATEMENT BY APPLICANT PTO FORM 1449	Atty. Docket No. 1662/60903	Serial No. 10/649,399
	Applicant(s) Dolitzky et al.	
	Filing Date August 26, 2003	Group 1624



U. S. PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE*

* - If pertinent

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
						YES	NO
MW	0 885 223 B1	Dec. 23, 1998	Europe				
MW	WO 97/29108	Aug. 14, 1997	PCT				

* Copy of reference is not enclosed because reference is cited in Search Report (copy of reference provided by International Searching Authority).

OTHER DOCUMENTS

EXAMINER'S INITIALS	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	M. R. Harnden et al., Nucleosides & Nucleotides 9(4):499-513 (1990)
MW	John Halebian et al "Pharmaceutical Applications of Polymorphism"; Journal of Pharmaceutical Sciences, Vol. 58, No. 8, August 1969 - PP.911 - 929.
MW	John K. Halebian "Characterization of Habits and Crystalline Modification of Solids and Their Pharmaceutical Applications"; Journal of Pharmaceutical Sciences, Vol. 64, No. 8, August 1975 - PP1269 - 1288.
MW	G. Michael Wall "Pharmaceutical Applications of Drug Crystal Studies", Pharmaceutical Manufacturing, Vol. 3, No.2, February 1986; PP 33-42.

EXAMINER	<i>Marie Ban</i>	DATE CONSIDERED <i>4/11/00</i>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		